Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development

Despite being the least abundant immunoglobulin G in human plasma, IgG4 are used therapeutically when weak effector functions are needed. The increase in engineered IgG4-based antibodies on the market led us to study the patent landscape of IgG4 Fc engineering, i.e., patents claiming modifications i...

Descripción completa

Detalles Bibliográficos
Autores principales: Dumet, Christophe, Pottier, Jérémy, Gouilleux-Gruart, Valérie, Watier, Hervé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816381/
https://www.ncbi.nlm.nih.gov/pubmed/31556789
http://dx.doi.org/10.1080/19420862.2019.1664365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816381/
https://www.ncbi.nlm.nih.gov/pubmed/31556789
http://dx.doi.org/10.1080/19420862.2019.1664365

Ejemplares similares